A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler

被引:19
|
作者
Hughes, JR
Adams, EH
Franzon, MA
Maguire, MK
Guary, J
机构
[1] Univ Vermont, Dept Psychiat, Psychol & Family Practice, Burlington, VT 05401 USA
[2] Harris Interact, Rochester, NY USA
[3] Pfizer Consumer Healthcare, Morris Plains, NJ USA
关键词
D O I
10.1136/tc.2004.008367
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objective: To determine the incidence of off-label use of, abuse of, and dependence on prescription nicotine inhaler. Design: Prospective telephone and internet interviews for six months. Participants: 535 new inhaler users. Main outcome: Structured interview about off-label use ( that is, use of inhaler for non-cessation reasons or concurrent use of inhaler and cigarettes) and Diagnostic and statistical manual, fourth edition ( DSM-IV) and International classification of diseases, 10th edition ( ICD-10) criteria for abuse and dependence Results: Although many used inhaler and cigarettes concurrently at some time ( 43-55%), few used inhaler for non-cessation reasons ( 4-9%) and few persisted in off label use ( 8-16%; 95% confidence interval ( CI) 5% to 19%). No participant met ICD-10 criteria for harmful use/abuse ( 95% CI 0% to 3.3%). Eight subjects ( 1.4%) appeared to meet DSM-IV or ICD-10 criteria for dependence on inhaler, but none were found dependent in a clinical expert interview ( 95% CI 0% to 3.3%). Conclusions: Although transient concurrent use of inhaler and cigarettes often occurs, use for noncessation reasons, abuse and dependence are rare.
引用
收藏
页码:49 / 54
页数:6
相关论文
共 50 条
  • [31] Methylphenidate Off-label Use
    Trenque, T.
    [J]. DRUG SAFETY, 2012, 35 (10) : 891 - 891
  • [32] Off-label use of infliximab
    Onder, M.
    Salavastru, C.
    Fritz, K.
    [J]. HAUTARZT, 2013, 64 (10): : 757 - 761
  • [34] Off-Label Use Reimbursement
    Cohen, Joshua
    Wilson, Andrew
    Faden, Laura
    [J]. FOOD AND DRUG LAW JOURNAL, 2009, 64 (02) : 391 - 403
  • [35] Off-Label Use vs Off-Label Marketing of Drugs Part 1: Off-Label Use-Patient Harms and Prescriber Responsibilities
    Van Norman, Gail A.
    [J]. JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (02): : 224 - 233
  • [36] Off-label use in psychopharmacotherapy [Off-Label-Use in der Psychopharmakotherapie]
    Fritze J.
    Schmauss M.
    [J]. Der Nervenarzt, 2002, 73 (8) : 796 - 799
  • [37] Rituximab off-label use for immune diseases: a single-center prospective pharmacovigilance study
    Pugnet, G.
    Olivier, P.
    Brassat, D.
    Leveneur, Y.
    Paul, C.
    Cantagrel, A.
    Madaule, S.
    Brevet, F.
    Astudillo, L.
    Blancher, A.
    Congy, N.
    Lapeyre-Mestre, M.
    Montastruc, J. L.
    Arlet, P.
    Sailler, L.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 112 - 112
  • [38] Off-label Use of Drugs and Adverse Drug Reactions in Pediatric Units: A Prospective, Multicenter Study
    Pratico, Andrea D.
    Longo, Laura
    Mansueto, Silvana
    Gozzo, Lucia
    Barberi, Ignazio
    Tiralongo, Venera
    Salvo, Vincenzo
    Falsaperla, Raffaele
    Vitaliti, Giovanna
    La Rosa, Mario
    Leonardi, Salvatore
    Rotondo, Antonio
    Avola, Nicoletta
    Sgarlata, Debora
    Damiano, Annalisa
    Tirantello, Massimo
    Anzelmo, Gaspare
    Cipolla, Domenico
    Rizzo, Angelo
    Russo, Antonio
    Ruggieri, Martino
    Salomone, Salvatore
    Drago, Filippo
    [J]. CURRENT DRUG SAFETY, 2018, 13 (03) : 200 - 207
  • [39] Off-Label Use vs Off-Label Marketing Part 2: Off-Label Marketing- Consequences for Patients, Clinicians, and Researchers
    Van Norman, Gail A.
    [J]. JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (03): : 359 - 370
  • [40] Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics
    Christian Lenk
    Philipp Koch
    Hildegard Zappel
    Claudia Wiesemann
    [J]. European Journal of Pediatrics, 2009, 168 : 1473 - 1478